武田制药宣布其40亿美元TYK2药物在大型银屑病研究中取得成功。
Takeda says $4B TYK2 drug succeeds in large psoriasis studies
生物技术与制药领域的最新动态
Takeda says $4B TYK2 drug succeeds in large psoriasis studies
“It can’t wait until tomorrow”: How patient advocacy drives change - Illumina
Recent discoveries on the acquisition of the highest levels of human performance | Science
AQP5: A functional gastric cancer stem cell marker in mouse and human tumors | Science
Ancient genomes illuminate the origins and dynamic history of East Asian cattle | Science
Conformational landscape adaptations enable processive phosphorylation by Src family kinases | Science
Optimal perovskite vapor partitioning on textured silicon for high-stability tandem solar cells | Science
Identification of intestinal enteroendocrine cell subtypes and their associated hormones in zebrafish
Post-transcriptional suppression of the pioneer factor Zelda protects the adult Drosophila testis from activation of the ovary program
The master virulence regulator PhoP dictates carbon metabolism by controlling cyclic AMP synthesis in Salmonella
Paralogs of Slitrk cell adhesion molecules configure excitatory synapse specificity via distinct cellular mechanisms
2025: A year of resilience and resourcefulness
Atavistik raises $120M for bleeding disorder, blood cancer drugs
Insilico advances Hong Kong IPO, eyes $260M raise with Lilly's support
Is Waters Corporation stock a safe buy before earnings - Trade Volume Summary & AI Forecast Swing Trade Picks - Улправда
Osprey Private Wealth LLC Has $7.94 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO - MarketBeat
New LDHA inhibitors disclosed for autoimmune diseases
Alicorn Pharmaceutical discovers new PRMT5 inhibitors
The leading GLP-1 contenders in pharma’s race for an obesity pill
Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Disease Registry to Advance Real-World Evidence in Neurodegenerative Care - Business Wire